![Breaking News: Estrella Immunopharma Makes Medical History with Successful Treatment of First Patient using CD19-Redirected ARTEMIS® T-cells](https://marketsgonewild.com/wp-content/uploads/2024/12/Breaking-News-Estrella-Immunopharma-Makes-Medical-History-with-Successful-Treatment-of-First-Patient-using-CD19-Redirected-ARTEMIS®-T-cells-600x360.jpg)
Breaking News: Estrella Immunopharma Makes Medical History with Successful Treatment of First Patient using CD19-Redirected ARTEMIS® T-cells
Exciting News in the Fight Against Cancer: Estrella Immunopharma Announces Positive Results in Clinical Trial EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1…